Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL928337 | 0.99 | CHRNA7 (0.41) | CHRNA7PDE10AHTR3ACHRNB4CHRNA3 | |
| SCHEMBL928387 | 0.86 | CHRNA7 (0.42) | CHRNA7HTR3ACHRNB4CHRNA3NPC1 | |
| Bromide SCHEMBL928348 | 0.85 | CHRNA7 (0.41) | CHRNA7HTR3ACHRNB4CHRNA3NPC1 | |
| SCHEMBL927440 | 0.81 | CHRNA7 (0.43) | CHRNA7PDE10AHTR3ACHRNB4CHRNA3 | |
| SCHEMBL930768 | 0.78 | CHRNA7 (0.59) | CHRNA7HTR3ACHRNB4CHRNA3NPC1 | |
| SCHEMBL6323963 | 0.76 | CHRNA7 (0.71) | CHRNA7HTR3ACHRNB4CHRNA3CNR2 | |
| SCHEMBL930239 | 0.76 | CHRNA7 (0.41) | CHRNA7PDE10AHTR3ACHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL929584 | 0.75 | CHRNA7 (0.70) | CHRNA7HTR3ACHRNB4CHRNA3CNR2 | |
| Bromide SCHEMBL928336 | 0.75 | CHRNA7 (0.70) | CHRNA7HTR3ACHRNB4CHRNA3CNR2 | |
| SCHEMBL928323 | 0.74 | NPC1 (0.45) | CHRNA7PDE10ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | ABBOTT LABORATORIES | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065178-A1 | Substituted diazabicycloakane derivatives | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885PDE10A 1088/4885HTR3A 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.